Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
01 4Aimix
02 8Aprovel
03 2Aprovel/Avapro
04 1Aprovel/CoAprovel
05 4Avapro
06 5Irbetan Franchise
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2019 Revenue in Millions : 735
2018 Revenue in Millions : 711
Growth (%) : 3
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 670
2019 Revenue in Millions : 815
Growth (%) : -18
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 461
2020 Revenue in Millions : 604
Growth (%) : -24
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2022 Revenue in Millions : 524
2021 Revenue in Millions : 461
Growth (%) : 14
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2023 Revenue in Millions : 450
2022 Revenue in Millions : 524
Growth (%) : -13
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2024 Revenue in Millions : 431
2023 Revenue in Millions : 450
Growth (%) : -4
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Irbesartan, Irbesartan+Hydrochlorothiazide
Main Therapeutic Indication : Antihypertensives
Currency : USD
2014 Revenue in Millions : -17.60%
2013 Revenue in Millions :
Growth (%) :
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Irbesartan, Irbesartan+Hydrochlorothiazide
Main Therapeutic Indication : Antihypertensives
Currency : USD
2015 Revenue in Millions : 800
2014 Revenue in Millions : 838
Growth (%) : 5%
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Irbesartan, Irbesartan+Hydrochlorothiazide
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2016 Revenue in Millions : 722
2015 Revenue in Millions : 808
Growth (%) : -11
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Irbesartan, Irbesartan + Hydrochlorothiazide
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2017 Revenue in Millions : 857
2016 Revenue in Millions : 844
Growth (%) : 1
